CT and MR imaging diagnosis and staging of hepatocellular carcinoma: Part I. Development, growth, and spread: Key pathologic and imaging aspects

Radiology

Volumn 272, Issue 3, 2014, Pages 635-654

  Choi, Jin Young ^a   Lee, Jeong Min ^b   Sirlin, Claude B ^c  

^a Yonsei University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84906875406     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14132361     Document Type: Review

References (141)

1. van Malenstein H, van Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. Eur J Cancer 2011;47(12):1789-1797.
2. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139(10):817-823.
3. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005;19(1):3-23. (Pubitemid 40331495)
4. Kudo M. Real practice of hepatocellular carcinoma in Japan: conclusions of the Japan Society of Hepatology 2009 Kobe Congress. Oncology 2010;78(Suppl 1):180-188.
5. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981;2(8256):1129-1133.
6. Theise ND, Curado MP, Franceschi S, et al. Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Cassification of Tumours of the Digestive System. 4th ed. Lyon, France: IARC, 2010; 205-216.
7. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365(12):1118- 1127.
8. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56(6):1384-1391.
9. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15(2):223-243, vii-x.
10. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011;54(1):173-184.
11. Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis 2008;29(7):1299- 1305.
12. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020-1022.
13. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56(4):908-943.
14. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4(2):439-474.
15. Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol 2013;29(3):285-292.
16. Marrero JA, Welling T. Modern diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2009;13(2):233-247.
17. Nishida N, Goel A. Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics 2011;12(2):130-137.
18. Libbrecht L, Craninx M, Nevens F, Desmet V, Roskams T. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 2001;39(1):66-73. (Pubitemid 32848276)
19. Park YN. Update on precursor and early lesions of hepatocellular carcinomas. Arch Pathol Lab Med 2011;135(6):704-715.
20. Brody RI, Theise ND. An inflammatory proposal for hepatocarcinogenesis. Hepatology 2012;56(1):382-384.
21. Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol 2013;87(2):227-247.
22. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31(4):339-346. (Pubitemid 35154440)
23. Theise ND. Macroregenerative (dysplastic) nodules and hepatocarcinogenesis: theoretical and clinical considerations. Semin Liver Dis 1995;15(4):360-371.
24. Theise ND. Cirrhosis and hepatocellular neoplasia: more like cousins than like parent and child. Gastroenterology 1996;111(2):526-528. (Pubitemid 26256744)
25. Sun M, Eshleman JR, Ferrell LD, et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology 2001;33(6):1415-1424. (Pubitemid 32496978)
26. Aihara T, Noguchi S, Sasaki Y, Nakano H, Imaoka S. Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis. Gastroenterology 1994;107(6): 1805-1811. (Pubitemid 24357637)
27. Frenette C, Gish RG. Hepatocellular carcinoma: molecular and genomic guideline for the clinician. Clin Liver Dis 2011;15(2): 307-321, vii-x.
28. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012;57(1):69-76.
29. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003;3(6):573-588. (Pubitemid 37168599)
30. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995;22(3):983-993.
31. Taguchi K, Asayama Y, Aishima S, et al. Morphologic approach to hepatocellular carcinoma development in man: de novo or the so-called 'dysplastic nodule-carcinoma' sequence? Oncol Rep 2002;9(4):737-743.
32. Park YN, Kim MJ. Hepatocarcinogenesis: imaging-pathologic correlation. Abdom Imaging 2011;36(3):232-243.
33. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49(2):658-664.
34. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42(5):1208-1236. (Pubitemid 43112690)
35. Kobayashi M, Ikeda K, Hosaka T, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer 2006;106(3):636-647. (Pubitemid 43157628)
36. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010;30(1):17-25.
37. Sakamoto M. Pathology of early hepatocellular carcinoma. Hepatol Res 2007;37(Suppl 2): S135-S138.
38. Nakashima O, Sugihara S, Kage M, Kojiro M. Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 1995;22(1):101-105.
39. Khalili K, Kim TK, Jang HJ, Yazdi LK, Guindi M, Sherman M. Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: biopsy for all, some, or none? Hepatology 2011;54(6):2048-2054.
40. Stevens WR, Gulino SP, Batts KP, Stephens DH, Johnson CD. Mosaic pattern of hepatocellular carcinoma: histologic basis for a characteristic CT appearance. J Comput Assist Tomogr 1996;20(3):337-342. (Pubitemid 26142280)
41. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27(1):55-76.
42. Kojiro M. Histopathology of liver cancers. Best Pract Res Clin Gastroenterol 2005;19(1):39-62. (Pubitemid 40331497)
43. Yano H, Iemura A, Fukuda K, Mizoguchi A, Haramaki M, Kojiro M. Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells. Hepatology 1993;18(2):320-327. (Pubitemid 23225103)
44. Okusaka T, Okada S, Ueno H, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 2002;95(9):1931-1937. (Pubitemid 35222173)
45. Wang J, Li Q, Sun Y, et al. Clinicopathologic features between multicentric occurence and intrahepatic metastasis of multiple hepatocellular carcinomas related to HBV. Surg Oncol 2009;18(1):25-30.
46. Park YN, Yang CP, Fernandez GJ, Cubukcu O, Thung SN, Theise ND. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am J Surg Pathol 1998;22(6):656-662. (Pubitemid 28280267)
47. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005;25(2):133-142. (Pubitemid 40781066)
48. Asayama Y, Yoshimitsu K, Irie H, et al. Poorly versus moderately differentiated hepatocellular carcinoma: vascularity assessment by computed tomographic hepatic angiography in correlation with histologically counted number of unpaired arteries. J Comput Assist Tomogr 2007;31(2):188-192. (Pubitemid 46573353)
49. El-Assal ON, Yamanoi A, Soda Y, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998;27(6):1554-1562. (Pubitemid 28264678)
50. Ueda K, Matsui O, Kawamori Y, et al. Hypervascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology 1998;206(1):161-166. (Pubitemid 28063001)
51. Kitao A, Zen Y, Matsui O, Gabata T, Nakanuma Y. Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography - radiologic-pathologic correlation. Radiology 2009;252(2):605-614.
52. Matsui O, Kobayashi S, Sanada J, et al. Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiographyassisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 2011;36(3):264-272.
53. Kadoya M, Matsui O, Takashima T, Nonomura A. Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology 1992;183(3):819-825.
54. Ishigami K, Yoshimitsu K, Nishihara Y, et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology 2009;250(2):435-443.
55. Ishizaki M, Ashida K, Higashi T, et al. The formation of capsule and septum in human hepatocellular carcinoma. Virchows Arch 2001;438(6):574-580. (Pubitemid 32662376)
56. Imaeda T, Kanematsu M, Mochizuki R, Goto H, Saji S, Shimokawa K. Extracapsular invasion of small hepatocellular carcinoma: MR and CT findings. J Comput Assist Tomogr 1994;18(5):755-760. (Pubitemid 24286368)
57. Ng IO, Lai EC, Ng MM, Fan ST. Tumor encapsulation in hepatocellular carcinoma. A pathologic study of 189 cases. Cancer 1992;70(1):45-49.
58. Lim JH, Choi D, Park CK, Lee WJ, Lim HK. Encapsulated hepatocellular carcinoma: CT-pathologic correlations. Eur Radiol 2006;16(10):2326-2333. (Pubitemid 44349881)
59. Iguchi T, Aishima S, Sanefuji K, et al. Both fibrous capsule formation and extracapsular penetration are powerful predictors of poor survival in human hepatocellular carcinoma: a histological assessment of 365 patients in Japan. Ann Surg Oncol 2009;16(9):2539-2546.
60. Takayama T, Makuuchi M, Hirohashi S, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990;336(8724):1150- 1153. (Pubitemid 20362906)
61. Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 2000;33(2):282-289. (Pubitemid 30485232)
62. Salomao M, Remotti H, Vaughan R, Siegel AB, Lefkowitch JH, Moreira RK. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 2012;43(5):737-746.
63. Zhang J, Krinsky GA. Iron-containing nodules of cirrhosis. NMR Biomed 2004;17(7):459-464. (Pubitemid 39549423)
64. Terada T, Kadoya M, Nakanuma Y, Matsui O. Iron-accumulating adenomatous hyperplastic nodule with malignant foci in the cirrhotic liver. Histopathologic, quantitative iron, and magnetic resonance imaging in vitro studies. Cancer 1990;65(9):1994-2000. (Pubitemid 20147639)
65. Gurusamy K. Trace element concentration in primary liver cancers - a systematic review. Biol Trace Elem Res 2007;118(3):191-206. (Pubitemid 47556617)
66. Nassif A, Jia J, Keiser M, et al. Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acidenhanced MR imaging. Radiology 2012;264(3):741-750.
67. Kitao A, Matsui O, Yoneda N, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 2011;21(10):2056-2066.
68. Kogita S, Imai Y, Okada M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010;20(10):2405-2413.
69. Tsuboyama T, Onishi H, Kim T, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging - correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010;255(3):824-833.
70. Vasuri F, Golfieri R, Fiorentino M, et al. OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation. Virchows Arch 2011;459(2):141-146.
71. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006;49(2):138-151. (Pubitemid 44079697)
72. Tsuda N, Matsui O. Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi - gadoxetic acidenhanced MR imaging. Radiology 2010;256(3):767-773.
73. Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging - correlation with molecular transporters and histopathologic features. Radiology 2010;256(3):817-826.
74. Nakashima Y, Nakashima O, Tanaka M, Okuda K, Nakashima M, Kojiro M. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res 2003;26(2):142-147. (Pubitemid 36927185)
75. Sakon M, Nagano H, Nakamori S, et al. Intrahepatic recurrences of hepatocellular carcinoma after hepatectomy: analysis based on tumor hemodynamics. Arch Surg 2002;137(1):94-99. (Pubitemid 34041828)
76. Okuda K. Hepatocellular carcinoma: clinicopathological aspects. J Gastroenterol Hepatol 1997;12(9-10):S314-S318. (Pubitemid 27504907)
77. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7(3):462-503.
78. Pomfret EA, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16(3):262-278.
79. Shin WY, Suh KS, Lee HW, et al. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2010;16(5):678-684.
80. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 2003;197(5):753-758. (Pubitemid 38199576)
81. Llovet JM, Fuster J, Bruix J; Barcelona-Clínic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10(2 Suppl 1):S115-S120.
82. Kojiro M, Kawabata K, Kawano Y, Shirai F, Takemoto N, Nakashima T. Hepatocellular carcinoma presenting as intrabile duct tumor growth: a clinicopathologic study of 24 cases. Cancer 1982;49(10):2144-2147. (Pubitemid 12100748)
83. Iguchi T, Aishima S, Taketomi A, et al. Extracapsular penetration is a new prognostic factor in human hepatocellular carcinoma. Am J Surg Pathol 2008;32(11):1675-1682.
84. Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K, Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology 1991;14(5):802-805.
85. Schima W, Kulinna C, Ba-Ssalamah A, Grünberger T. Multidetector computed tomography of the liver [in German]. Radiologe 2005;45(1):15-23. (Pubitemid 40174999)
86. Frydrychowicz A, Lubner MG, Brown JJ, et al. Hepatobiliary MR imaging with gado-linium- based contrast agents. J Magn Reson Imaging 2012;35(3):492-511.
87. Miraglia R, Pietrosi G, Maruzzelli L, et al. Predictive factors of tumor response to transcatheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. World J Gastroenterol 2007;13(45):6022-6026. (Pubitemid 350238269)
88. Kim MJ, Choi JY, Lim JS, et al. Optimal scan window for detection of hypervascular hepatocellular carcinomas during MDCT examination. AJR Am J Roentgenol 2006;187(1):198-206.
89. Ichikawa T, Kitamura T, Nakajima H, et al. Hypervascular hepatocellular carcinoma: can double arterial phase imaging with multidetector CT improve tumor depiction in the cirrhotic liver? AJR Am J Roentgenol 2002;179(3):751-758. (Pubitemid 34919593)
90. Earls JP, Rofsky NM, DeCorato DR, Krinsky GA, Weinreb JC. Hepatic arterial-phase dynamic gadolinium-enhanced MR imaging: optimization with a test examination and a power injector. Radiology 1997;202(1):268-273. (Pubitemid 27024138)
91. Hong HS, Kim HS, Kim MJ, De Becker J, Mitchell DG, Kanematsu M. Single breathhold multiarterial dynamic MRI of the liver at 3T using a 3D fat-suppressed keyhole technique. J Magn Reson Imaging 2008;28(2):396-402.
92. Murakami T, Hori M, Kim T, Kawata S, Abe H, Nakamura H. Multidetector row CT and MR imaging in diagnosing hepatocellular carcinoma. Intervirology 2004; 47(3-5):209-226. (Pubitemid 39279461)
93. Iannaccone R, Laghi A, Catalano C, et al. Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology 2005;234(2):460-467. (Pubitemid 40139917)
94. Rimola J, Forner A, Reig M, et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 2009;50(3):791-798.
95. Lim JH, Choi D, Kim SH, et al. Detection of hepatocellular carcinoma: value of adding delayed phase imaging to dual-phase helical CT. AJR Am J Roentgenol 2002;179(1):67-73. (Pubitemid 34694813)
96. Takayasu K, Furukawa H, Wakao F, et al. CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. AJR Am J Roentgenol 1995;164(4):885-890.
97. Doyle DJ, O'Malley ME, Jang HJ, Jhaveri K. Value of the unenhanced phase for detection of hepatocellular carcinomas 3 cm or less when performing multiphase computed tomography in patients with cirrhosis. J Comput Assist Tomogr 2007;31(1):86-92. (Pubitemid 46183345)
98. Davies BE, Kirchin MA, Bensel K, et al. Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function. Invest Radiol 2002; 37(5):299-308. (Pubitemid 34461676)
99. Swan SK, Lambrecht LJ, Townsend R, et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 1999;34(7):443-448. (Pubitemid 29302836)
100. Ringe KI, Husarik DB, Sirlin CB, Merkle EM. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010;195(1):13-28.
101. Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol 2009;193(4):1053-1060.
102. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid - enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005;234(2):468-478. (Pubitemid 40139918)
103. Tsuda N, Harada K, Matsui O. Effect of change in transporter expression on gad-olinium- ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging during hepatocarcinogenesis in rats. J Gastroenterol Hepatol 2011;26(3):568-576.
104. Tanimoto A, Kuwatsuru R, Kadoya M, et al. Evaluation of gadobenate dimeglumine in hepatocellular carcinoma: results from phase II and phase III clinical trials in Japan. J Magn Reson Imaging 1999;10(3):450-460. (Pubitemid 29463131)
105. Libra A, Fernetti C, Lorusso V, et al. Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver. J Pharmacol Exp Ther 2006;319(2):809-817.
106. Bartolozzi C, Battaglia V, Bozzi E. Hepatocellular nodules in liver cirrhosis: con-trast- enhanced MR. Abdom Imaging 2011;36(3):290-299.
107. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40(11):715-724. (Pubitemid 41546838)
108. Filippone A, Blakeborough A, Breuer J, et al. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging 2010;31(2):356-364.
109. Tanimoto A, Higuchi N, Ueno A. Reduction of ringing artifacts in the arterial phase of gadoxetic acid-enhanced dynamic MR im aging. Magn Reson Med Sci 2012;11(2):91-97.
110. Svensson J, Petersson JS, Ståhlberg F, Larsson EM, Leander P, Olsson LE. Image artifacts due to a time-varying contrast medium concentration in 3D contrast-enhanced MRA. J Magn Reson Imaging 1999;10(6):919-928.
111. Schmid-Tannwald C, Herrmann K, Oto A, Panteleon A, Reiser M, Zech C. Optimization of the dynamic, Gd-EOB-DTPA-enhanced MRI of the liver: the effect of the injection rate. Acta Radiol 2012;53(9):961-965.
112. Tamada T, Ito K, Yoshida K, et al. Comparison of three different injection methods for arterial phase of Gd-EOB-DTPA enhanced MR imaging of the liver. Eur J Radiol 2011;80(3):e284-e288.
113. Davenport MS, Viglianti BL, Al-Hawary MM, et al. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology 2013;266(2):452-461.
114. Kühn JP, Hegenscheid K, Siegmund W, Froehlich CP, Hosten N, Puls R. Normal dynamic MRI enhancement patterns of the upper abdominal organs: gadoxetic acid compared with gadobutrol. AJR Am J Roentgenol 2009;193(5):1318-1323.
115. Tanimoto A, Lee JM, Murakami T, Huppertz A, Kudo M, Grazioli L. Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol 2009;19(Suppl 5):S975-S989.
116. Nakamura Y, Toyota N, Date S, et al. Clinical significance of the transitional phase at gadoxetate disodium-enhanced hepatic MRI for the diagnosis of hepatocellular carcinoma: preliminary results. J Comput Assist Tomogr 2011;35(6):723-727.
117. Krinsky GA, Lee VS, Nguyen MT, et al. Siderotic nodules at MR imaging: regenerative or dysplastic? J Comput Assist Tomogr 2000;24(5):773-776. (Pubitemid 32204309)
118. Xu PJ, Yan FH, Wang JH, Shan Y, Ji Y, Chen CZ. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr 2010;34(4):506-512.
119. Krinsky GA, Israel G. Nondysplastic nodules that are hyperintense on T1-weighted gradient-echo MR imaging: frequency in cirrhotic patients undergoing transplantation. AJR Am J Roentgenol 2003;180(4):1023-1027. (Pubitemid 36363044)
120. Hamilton SR, Aaltonen LA. Tumours of the liver and intrahepatic bile ducts. In: World Health Organization Classification of Tumours. Lyon, France: IARC, 2000; 159-172.
121. Murakami T, Nakamura H, Hori S, et al. CT and MRI of siderotic regenerating nodules in hepatic cirrhosis. J Comput Assist Tomogr 1992;16(4):578-582.
122. Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. RadioGraphics 2008;28(3):747-769.
123. Freeny PC, Grossholz M, Kaakaji K, Schmiedl UP. Significance of hyperattenuating and contrast-enhancing hepatic nodules detected in the cirrhotic liver during arterial phase helical CT in pre-liver transplant patients: radiologic-histopathologic correlation of explanted livers. Abdom Imaging 2003;28(3):333-346. (Pubitemid 36676164)
124. Tsuda N, Matsui O. Signal profile on Gd-EOB-DTPA-enhanced MR imaging in non-alcoholic steatohepatitis and liver cirrhosis induced in rats: correlation with transporter expression. Eur Radiol 2011;21(12):2542-2550.
125. Manfredi R, Maresca G, Baron RL, et al. Gadobenate dimeglumine (BOPTA) enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. J Magn Reson Imaging 1998;8(4):862-867. (Pubitemid 28357594)
126. Lim JH, Choi BI. Dysplastic nodules in liver cirrhosis: imaging. Abdom Imaging 2002;27(2):117-128. (Pubitemid 36460681)
127. Baron RL, Peterson MS. From the RSNA refresher courses: screening the cirrhotic liver for hepatocellular carcinoma with CT and MR imaging: opportunities and pitfalls. RadioGraphics 2001;21(Spec No):S117-S132.
128. Martín J, Puig J, Darnell A, Donoso L. Magnetic resonance of focal liver lesions in hepatic cirrhosis and chronic hepatitis. Semin Ultrasound CT MR 2002;23(1):62-78.
129. Earls JP, Theise ND, Weinreb JC, et al. Dysplastic nodules and hepatocellular carcinoma: thin-section MR imaging of explanted cirrhotic livers with pathologic correlation. Radiology 1996;201(1):207-214. (Pubitemid 26314389)
130. Ito K, Mitchell DG, Gabata T, et al. Hepatocellular carcinoma: association with increased iron deposition in the cirrhotic liver at MR imaging. Radiology 1999;212(1):235-240. (Pubitemid 29302541)
131. Martín J, Sentís M, Zidan A, et al. Fatty metamorphosis of hepatocellular carcinoma: detection with chemical shift gradientecho MR imaging. Radiology 1995;195(1):125-130.
132. Rimola J, Forner A, Tremosini S, et al. Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol 2012;56(6):1317- 1323.
133. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008;247(2):311-330.
134. Park MJ, Kim YK, Lee MH, Lee JH. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<=5 2.0 cm) in patients with hepatitisinduced liver cirrhosis. Acta Radiol 2013;54(2):127-136.
135. Kim T, Baron RL, Nalesnik MA. Infarcted regenerative nodules in cirrhosis: CT and MR imaging findings with pathologic correlation. AJR Am J Roentgenol 2000;175(4):1121-1125.
136. Takeshita K, Nagashima I, Frui S, et al. Effect of superparamagnetic iron oxideenhanced MRI of the liver with hepatocellular carcinoma and hyperplastic nodule. J Comput Assist Tomogr 2002;26(3):451-455. (Pubitemid 34564228)
137. Honda H, Tajima T, Kajiyama K, et al. Vascular changes in hepatocellular carcinoma: correlation of radiologic and pathologic findings. AJR Am J Roentgenol 1999;173(5):1213-1217. (Pubitemid 29493992)
138. Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002;225(1):143-149.
139. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47(1):97-104. (Pubitemid 351171046)
140. Ito K. Hepatocellular carcinoma: conventional MRI findings including gadoliniumenhanced dynamic imaging. Eur J Radiol 2006;58(2):186-199.
141. Golfieri R, Grazioli L, Orlando E, et al. Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. J Magn Reson Imaging 2012;36(3):648-657.